NCT05467943CompletedPhase 2
Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma
A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Tazemetostat for the Treatment of Patients With Relapsed/Refractory Follicular Lymphoma
Source: ClinicalTrials.gov · Last updated 23 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Treating Relapsed/Refractory Follicular Lymphoma with Tazemetostat
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- First submitted
- 28 Jun 2022
- Start date
- 29 Jul 2022
- Primary completion date
- 30 Nov 2024
- Lead sponsor
- Hutchmed
- Diseases
- Follicular lymphoma
- NCT number
- NCT05467943
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 42
- From 29 Jul 2022 to the primary completion date, 30 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous use of Tazemetostat or other EZH2 inhibitors;
- Previous bone marrow malignancies,
Other
- Patients with invasion of lymphoma to the central nervous system (CNS) or the pia mater;
- Abnormalities associated with MDS and myeloproliferative neoplasms observed by cytogenetic testing and DNA sequencing;
Who the study is looking for
- Fully aware this study and signed the informed consent form in voluntary manner, and willing and able to comply with the study procedure;
- Age ≥18 years;
- Patients with histologically confirmed R/R FL (Grades 1, 2, 3a)
- Patients must have one measurable lesion
- Life expectancy ≥ 12 weeks;
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2
- Adequate bone marrow function, renal function and hepatic function:
- Currently human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or cytomegalovirus (CMV) is inactive:
- Female patients of childbearing potential must agree to adopt dual contraceptive method
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.